IN165717B
(sk)
*
|
1986-08-07 |
1989-12-23 |
Battelle Memorial Institute |
|
US5529932A
(en)
*
|
1988-01-28 |
1996-06-25 |
Pharmacia, S.P.A. |
Isolated DNA encoding a plant ribosome inactivating protein from the leaves of saponaria officinalis
|
IL106992A
(en)
*
|
1988-02-11 |
1994-06-24 |
Bristol Myers Squibb Co |
Noble hydrazonic history of anthracycline and methods for their preparation
|
DE4004573A1
(de)
*
|
1989-02-17 |
1990-08-23 |
Tanabe Seiyaku Co |
Neues versuchstier und seine herstellung
|
US5354844A
(en)
*
|
1989-03-16 |
1994-10-11 |
Boehringer Ingelheim International Gmbh |
Protein-polycation conjugates
|
US5191067A
(en)
*
|
1989-04-27 |
1993-03-02 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
IL95031A
(en)
|
1989-07-18 |
2007-03-08 |
Amgen Inc |
A method of producing a recombinant human necrotic factor absorber
|
ATE120374T1
(de)
*
|
1989-07-20 |
1995-04-15 |
Sandoz Ag |
Markierte polypeptidderivate.
|
US5208323A
(en)
*
|
1989-08-10 |
1993-05-04 |
Universite Laval |
Coupling of an anti-tumor to an antibody using glutaraldehyde preactivated anti-tumor agent
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
EP0497867A1
(en)
*
|
1989-10-23 |
1992-08-12 |
Schering Corporation |
Polypeptide inhibitors of gamma interferon
|
DE69132581T3
(de)
*
|
1990-03-02 |
2008-07-17 |
Boston Medical Center Corp., Boston |
Verbesserte chimäre toxine
|
US6552170B1
(en)
|
1990-04-06 |
2003-04-22 |
Amgen Inc. |
PEGylation reagents and compounds formed therewith
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
DK0485563T3
(da)
*
|
1990-05-30 |
1995-03-20 |
Deutsches Krebsforsch |
Polyethersubstituerede antitumormidler
|
IL98528A0
(en)
*
|
1990-06-21 |
1992-07-15 |
Merck & Co Inc |
Pharmaceutical compositions containing hybrid for killing bladder cancer cells
|
CA2086679A1
(en)
*
|
1990-07-05 |
1992-01-06 |
Hermanus A. M. Verheul |
Receptor directed-toxin conjugates
|
US5478804A
(en)
*
|
1990-09-19 |
1995-12-26 |
The Salk Institute For Biological Studies |
Treatment of tumorigenic pathophysiological conditions with FGF-cytoxic conjugates
|
ATE152917T1
(de)
*
|
1990-09-28 |
1997-05-15 |
Neorx Corp |
Polymere träger zur freisetzung kovalent gebundener wirkstoffe
|
US5431899A
(en)
*
|
1991-02-04 |
1995-07-11 |
University Of Saskatchewan |
Rotavirus VP6 as a diagnostic and targeting agent
|
US5464753A
(en)
*
|
1991-03-08 |
1995-11-07 |
Univ Illinois |
Purification and manipulation of bone marrow and blood cells on the basis of P-glycoprotein expression
|
JP3693671B2
(ja)
*
|
1991-03-15 |
2005-09-07 |
アムゲン インコーポレーテッド |
ポリペプチドのpeg化
|
AU662155B2
(en)
*
|
1991-05-10 |
1995-08-24 |
Celtrix Pharmaceuticals, Inc. |
Targeted delivery of bone growth factors
|
ES2075402T3
(es)
*
|
1991-07-22 |
1995-10-01 |
Bracco Int Bv |
Conjugados quelados con metales paramagneticos para enfoque deliberado.
|
US5521291A
(en)
*
|
1991-09-30 |
1996-05-28 |
Boehringer Ingelheim International, Gmbh |
Conjugates for introducing nucleic acid into higher eucaryotic cells
|
US5981273A
(en)
*
|
1991-09-30 |
1999-11-09 |
Boehringer Ingelheim Int'l. Gmbh |
Composition comprising an endosomolytic agent for introducing nucleic acid complexes into higher eucaryotic cells
|
NZ244306A
(en)
*
|
1991-09-30 |
1995-07-26 |
Boehringer Ingelheim Int |
Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation
|
US5922859A
(en)
*
|
1992-02-01 |
1999-07-13 |
Boehringer Ingelheim International Gmbh |
Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells
|
EP0563475B1
(en)
*
|
1992-03-25 |
2000-05-31 |
Immunogen Inc |
Cell binding agent conjugates of derivatives of CC-1065
|
US5679350A
(en)
*
|
1992-05-28 |
1997-10-21 |
The University Of Toledo |
Method of delivery of a medicament to a cancer cell using a pathway of plasminogen activator material
|
EP0643584B1
(en)
*
|
1992-05-28 |
2000-03-15 |
The University Of Toledo |
Delivery of a cytotoxic compound to a cancer cell using a pathway of plasminogen activator material
|
US5916772A
(en)
*
|
1992-06-16 |
1999-06-29 |
Whittier Institute For Diabetes And Endocrinology |
Recombinant production of saporin-containing proteins
|
US5393737A
(en)
*
|
1992-08-20 |
1995-02-28 |
Health Research, Inc. |
Cytotoxic drug conjugates for treatment of neoplastic diseases
|
ZA936478B
(en)
*
|
1992-09-03 |
1994-09-30 |
Regeneron Pharma |
Dorsal tissue affecting factor and compositions
|
US5466672A
(en)
*
|
1992-12-04 |
1995-11-14 |
Ophidian Pharmaceuticals, Inc. |
Therapeutic use of clostridium difficile toxin A
|
US6001364A
(en)
*
|
1993-05-05 |
1999-12-14 |
Gryphon Sciences |
Hetero-polyoxime compounds and their preparation by parallel assembly
|
US6174530B1
(en)
|
1993-05-05 |
2001-01-16 |
Gryphon Sciences |
Homogeneous polyoxime compositions and their preparation by parallel assembly
|
DK0697891T3
(da)
|
1993-05-05 |
2000-09-04 |
Keith Rose |
Polyoximforbindelser og fremstilling deraf
|
US6214345B1
(en)
*
|
1993-05-14 |
2001-04-10 |
Bristol-Myers Squibb Co. |
Lysosomal enzyme-cleavable antitumor drug conjugates
|
US5502037A
(en)
*
|
1993-07-09 |
1996-03-26 |
Neuromed Technologies, Inc. |
Pro-cytotoxic drug conjugates for anticancer therapy
|
US6491905B1
(en)
*
|
1993-09-14 |
2002-12-10 |
The Uab Research Foundation |
Recombinant bacterial cells for delivery of PNP to tumor cells
|
DE69425356T2
(de)
*
|
1993-09-22 |
2002-04-18 |
Hoechst Ag |
Pro-Prodrugs, ihre Herstellung und Anwendung
|
US5962220A
(en)
*
|
1993-10-26 |
1999-10-05 |
Thomas Jefferson University |
Compositions that specifically bind to colorectal cells and methods of using the same
|
US5879656A
(en)
*
|
1993-10-26 |
1999-03-09 |
Thomas Jefferson University |
Methods of treating metastatic colorectal cancer with ST receptor binding compounds
|
US7097839B1
(en)
*
|
1993-10-26 |
2006-08-29 |
Thomas Jefferson University |
ST receptor binding compounds and methods of using the same
|
CA2137639C
(en)
*
|
1993-12-09 |
1999-01-26 |
Agustin B. L. Davila |
Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
US5587459A
(en)
*
|
1994-08-19 |
1996-12-24 |
Regents Of The University Of Minnesota |
Immunoconjugates comprising tyrosine kinase inhibitors
|
US5911995A
(en)
*
|
1994-08-19 |
1999-06-15 |
Regents Of The University Of Minnesota |
EGF-genistein conjugates for the treatment of cancer
|
DE4433890C2
(de)
*
|
1994-09-22 |
1999-02-18 |
Deutsches Krebsforsch |
Konjugat aus einem Wirkstoff und einem nicht als körperfremd angesehenen, nativen Protein
|
ES2191719T3
(es)
*
|
1994-11-10 |
2003-09-16 |
Univ Kentucky Res Found |
Dispositivo implantable y recargable de descarga controlada para suministrar farmacos directamente a una parte interna del cuerpo.
|
US5766899A
(en)
*
|
1995-02-27 |
1998-06-16 |
Board Of Regents , The University Of Texas System |
Targeted nucleic acid delivery into liver cells
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
WO1997023243A1
(en)
*
|
1995-12-22 |
1997-07-03 |
Bristol-Myers Squibb Company |
Branched hydrazone linkers
|
US20050025740A1
(en)
*
|
1996-01-05 |
2005-02-03 |
Keith Rose |
Polyoxime compounds and their preparation
|
PL189698B1
(pl)
|
1996-03-12 |
2005-09-30 |
Pg Txl Co |
Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
|
US6441025B2
(en)
*
|
1996-03-12 |
2002-08-27 |
Pg-Txl Company, L.P. |
Water soluble paclitaxel derivatives
|
US6030941A
(en)
*
|
1996-05-01 |
2000-02-29 |
Avi Biopharma, Inc. |
Polymer composition for delivering substances in living organisms
|
TW555765B
(en)
|
1996-07-09 |
2003-10-01 |
Amgen Inc |
Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
|
US5952294A
(en)
*
|
1996-07-31 |
1999-09-14 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Peptidyl prodrugs and methods of making and using the same
|
DE19636889A1
(de)
|
1996-09-11 |
1998-03-12 |
Felix Dr Kratz |
Antineoplastisch wirkende Transferrin- und Albuminkonjugate zytostatischer Verbindungen aus der Gruppe der Anthrazykline, Alkylantien, Antimetabolite und Cisplatin-Analoga und diese enthaltende Arzneimittel
|
US6080383A
(en)
*
|
1997-01-13 |
2000-06-27 |
Rose; Samuel |
Method and composition for the treatment of cancer by the enzymatic conversion of soluble radioactive toxic agents into radioactive toxic precipitates in the cancer
|
WO1998047496A2
(en)
*
|
1997-04-18 |
1998-10-29 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US5965118A
(en)
*
|
1997-04-18 |
1999-10-12 |
Access Pharmaceuticals, Inc. |
Polymer-platinum compounds
|
US6916790B2
(en)
|
1997-05-05 |
2005-07-12 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
US6548482B1
(en)
|
1997-05-05 |
2003-04-15 |
Mayo Foundation For Medical Education And Research |
Treatment of osteoporosis
|
DE69835878T2
(de)
*
|
1997-05-05 |
2007-04-26 |
Mayo Foundation For Medical Education And Research, Rochester |
IGFIIE/ IGFBP2 Komplex
|
US6030997A
(en)
*
|
1998-01-21 |
2000-02-29 |
Eilat; Eran |
Acid labile prodrugs
|
US6866837B2
(en)
|
1998-06-05 |
2005-03-15 |
Mallinckrodt Inc. |
Radiolabeled peptides for the diagnosis and treatment of breast and prostate tumors and metastases of such tumors
|
AU764603B2
(en)
*
|
1998-07-17 |
2003-08-21 |
United States Of America, Represented By The Secretary, Department Of Health And Human Services, The |
Water-soluble drugs and methods for their production
|
US6747055B1
(en)
|
1998-07-17 |
2004-06-08 |
The United States Of America As Represented By The Department Of Health And Human Services |
Water-soluble drugs and methods for their production
|
GB9904582D0
(en)
*
|
1999-02-26 |
1999-04-21 |
Nycomed Imaging As |
Process
|
US7018654B2
(en)
*
|
1999-03-05 |
2006-03-28 |
New River Pharmaceuticals Inc. |
Pharmaceutical composition containing an active agent in an amino acid copolymer structure
|
US7060708B2
(en)
*
|
1999-03-10 |
2006-06-13 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US6716452B1
(en)
*
|
2000-08-22 |
2004-04-06 |
New River Pharmaceuticals Inc. |
Active agent delivery systems and methods for protecting and administering active agents
|
US20010041189A1
(en)
*
|
1999-04-13 |
2001-11-15 |
Jingya Xu |
Poly(dipeptide) as a drug carrier
|
US6706892B1
(en)
|
1999-09-07 |
2004-03-16 |
Conjuchem, Inc. |
Pulmonary delivery for bioconjugation
|
US20030054977A1
(en)
*
|
1999-10-12 |
2003-03-20 |
Cell Therapeutics, Inc. |
Manufacture of polyglutamate-therapeutic agent conjugates
|
US7067111B1
(en)
*
|
1999-10-25 |
2006-06-27 |
Board Of Regents, University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
US20020077290A1
(en)
*
|
2000-03-17 |
2002-06-20 |
Rama Bhatt |
Polyglutamic acid-camptothecin conjugates and methods of preparation
|
CA2404431C
(en)
|
2000-03-27 |
2011-06-07 |
Thomas Jefferson University |
Guanylyl cyclase c in the detection of stomach and esophageal cancers
|
EP1286704B1
(en)
|
2000-06-02 |
2014-07-23 |
Board of Regents, The University of Texas System |
ETHYLENEDICYSTEINE (EC)-glucose analog CONJUGATES
|
CA2414650A1
(en)
*
|
2000-06-30 |
2002-01-10 |
Board Of Regents, The University Of Texas System |
Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
|
US20020099013A1
(en)
*
|
2000-11-14 |
2002-07-25 |
Thomas Piccariello |
Active agent delivery systems and methods for protecting and administering active agents
|
US7163918B2
(en)
|
2000-08-22 |
2007-01-16 |
New River Pharmaceuticals Inc. |
Iodothyronine compositions
|
BR0114713A
(pt)
*
|
2000-10-16 |
2004-01-13 |
Neopharm Inc |
Formulação lipossÈmica de mitoxantrona
|
US8394813B2
(en)
*
|
2000-11-14 |
2013-03-12 |
Shire Llc |
Active agent delivery systems and methods for protecting and administering active agents
|
KR20030074637A
(ko)
|
2000-12-01 |
2003-09-19 |
셀 웍스 인크. |
글리코실화/갈락토실화된 펩티드, 이관능기적 링커 , 및뉴클레오티드성 단량성/중합체의 접합체, 및 관련 조성물및 사용 방법
|
CU22999A1
(es)
|
2001-12-04 |
2004-10-12 |
Centro Inmunologia Molecular |
Método de tratamiento de enfermedades malignas e infecciosas crónicas
|
US20020197261A1
(en)
*
|
2001-04-26 |
2002-12-26 |
Chun Li |
Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
|
US7589180B2
(en)
|
2001-05-11 |
2009-09-15 |
Abbott Laboratories Inc. |
Specific binding proteins and uses thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
DE60213232T2
(de)
*
|
2001-05-15 |
2007-07-26 |
Faulk Pharmaceuticals, Inc., Indianapolis |
Gezielte freisetzung von arzneimitteln zur behandlung von virusinfektionen
|
EP1404334A4
(en)
*
|
2001-05-15 |
2005-02-02 |
Faulk Pharmaceuticals Inc |
TARGETED ADMINISTRATION OF BIOACTIVE COMPOUNDS FOR THE TREATMENT OF CANCER
|
CA2451511A1
(en)
*
|
2001-06-22 |
2003-01-03 |
The University Of British Columbia |
Antimitotic eleuthesides
|
US7169752B2
(en)
*
|
2003-09-30 |
2007-01-30 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US20060014697A1
(en)
*
|
2001-08-22 |
2006-01-19 |
Travis Mickle |
Pharmaceutical compositions for prevention of overdose or abuse
|
US20070066537A1
(en)
*
|
2002-02-22 |
2007-03-22 |
New River Pharmaceuticals Inc. |
Compounds and compositions for prevention of overdose of oxycodone
|
US7338939B2
(en)
*
|
2003-09-30 |
2008-03-04 |
New River Pharmaceuticals Inc. |
Abuse-resistant hydrocodone compounds
|
US7375082B2
(en)
*
|
2002-02-22 |
2008-05-20 |
Shire Llc |
Abuse-resistant hydrocodone compounds
|
US20030109432A1
(en)
*
|
2001-12-10 |
2003-06-12 |
Zuo William W. |
Anticancer polypeptide-metal complexes and compositions, methods of making, and methods of using same
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US7261875B2
(en)
*
|
2001-12-21 |
2007-08-28 |
Board Of Regents, The University Of Texas System |
Dendritic poly (amino acid) carriers and methods of use
|
US7700561B2
(en)
*
|
2002-02-22 |
2010-04-20 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
EP2266590A3
(en)
|
2002-02-22 |
2011-04-20 |
Shire LLC |
Active agent delivery sytems and methods for protecting and administering active agents
|
AU2003219863C1
(en)
*
|
2002-02-22 |
2009-03-05 |
Shire Llc |
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances
|
EP1481078A4
(en)
*
|
2002-02-22 |
2006-08-16 |
New River Pharmaceuticals Inc |
USE OF A PEPTIDE DRUG CONJUGATION TO REDUCE VARIABILITY OF MEDICAMENT SERUM MIRRORS BETWEEN PATIENTS
|
US7105486B2
(en)
*
|
2002-02-22 |
2006-09-12 |
New River Pharmaceuticals Inc. |
Abuse-resistant amphetamine compounds
|
US7659253B2
(en)
*
|
2002-02-22 |
2010-02-09 |
Shire Llc |
Abuse-resistant amphetamine prodrugs
|
EP1551372B8
(en)
|
2002-09-20 |
2018-08-01 |
Alpharma Pharmaceuticals LLC |
Sequestering subunit and related compositions and methods
|
US20040166058A1
(en)
*
|
2002-11-07 |
2004-08-26 |
Board Of Regents, The University Of Texas System |
Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
|
CA2524350C
(en)
*
|
2003-05-07 |
2015-04-14 |
Indiana University Research & Technology Corporation |
Alloyed semiconductor quantum dots and concentration-gradient alloyed quantum dots, series comprising the same and methods related thereto
|
EP1644019B2
(en)
*
|
2003-05-29 |
2018-02-21 |
Shire LLC |
Abuse resistant amphetamine compounds
|
US20070087959A1
(en)
*
|
2003-08-19 |
2007-04-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Method of inducing biomineralization method of inducing bone regeneration and methods related thereof
|
JP4691500B2
(ja)
*
|
2003-09-30 |
2011-06-01 |
シャイア エルエルシー |
過剰摂取又は乱用を防止するための薬学組成物
|
ATE516288T1
(de)
|
2003-10-22 |
2011-07-15 |
Us Gov Health & Human Serv |
Pyrrolobenzodiazepinderivate, zusammensetzungen, die diese enthalten, und damit in zusammenhang stehende verfahren
|
WO2005055931A2
(en)
|
2003-12-03 |
2005-06-23 |
University Of Medicine And Dentistry Of New Jersey |
Method of preventing survival of retrovirally cells and of inhibiting formation of infectious retroviruses
|
EP1695991B1
(en)
*
|
2003-12-10 |
2010-02-17 |
TOUDAI TLO, Ltd. |
Coordination complex of diaminocyclohexaneplatinum(ii) with block copolymer containing poly(carboxylic acid) segment and antitumor agent comprising the same
|
US9050378B2
(en)
*
|
2003-12-10 |
2015-06-09 |
Board Of Regents, The University Of Texas System |
N2S2 chelate-targeting ligand conjugates
|
NZ549990A
(en)
|
2004-04-07 |
2009-08-28 |
Rinat Neuroscience Copr |
Methods for treating bone cancer pain by administering a nerve growth factor antagonist
|
US20060036084A1
(en)
*
|
2004-08-04 |
2006-02-16 |
Lianhua Qu |
Conglomerated semiconductor nanocrystals
|
US8454927B2
(en)
*
|
2004-08-04 |
2013-06-04 |
Crystalplex Corporation |
Alloyed semiconductor nanocrystals
|
US7781607B2
(en)
*
|
2005-06-09 |
2010-08-24 |
Nanocarrier Co., Ltd. |
Method for producing polymerized coordination compounds of platinum complex
|
WO2007055902A1
(en)
|
2005-11-03 |
2007-05-18 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Immunogenic peptides and methods of use for treating and preventing cancer
|
WO2007067417A1
(en)
*
|
2005-12-05 |
2007-06-14 |
Nitto Denko Corporation |
Polyglutamate-amino acid conjugates and methods
|
US7820174B2
(en)
|
2006-02-24 |
2010-10-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9107863B2
(en)
*
|
2006-03-27 |
2015-08-18 |
The Buck Institute For Age Reasearch |
Reagents and methods for cancer treatment and prevention
|
US8758723B2
(en)
|
2006-04-19 |
2014-06-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for cellular imaging and therapy
|
EP2526932B1
(en)
|
2006-06-19 |
2017-06-07 |
Alpharma Pharmaceuticals LLC |
Pharmaceutical composition
|
WO2008039818A2
(en)
|
2006-09-26 |
2008-04-03 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Modified t cell receptors and related materials and methods
|
US10925977B2
(en)
|
2006-10-05 |
2021-02-23 |
Ceil>Point, LLC |
Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
|
AU2007329678A1
(en)
|
2006-10-31 |
2008-06-12 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Smoothened polypeptides and methods of use
|
WO2008089053A2
(en)
|
2007-01-12 |
2008-07-24 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Gp100-specific t cell receptors and related materials and methods of use
|
US9090693B2
(en)
*
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
US20080181852A1
(en)
*
|
2007-01-29 |
2008-07-31 |
Nitto Denko Corporation |
Multi-functional Drug Carriers
|
JP5618549B2
(ja)
|
2007-03-15 |
2014-11-05 |
ルードヴィッヒ インスティテュート フォー キャンサーリサーチ リミテッド |
Egfr抗体及びsrc阻害剤を用いる治療方法及び関連製剤
|
EP2144631A2
(en)
*
|
2007-04-10 |
2010-01-20 |
Nitto Denko Corporation |
Multi-functional polyglutamate drug carriers
|
DK2155254T3
(da)
*
|
2007-05-09 |
2013-03-04 |
Nitto Denko Corp |
Med platinlægemidler konjugerede polymere
|
WO2008141110A2
(en)
*
|
2007-05-09 |
2008-11-20 |
Nitto Denko Corporation |
Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
|
WO2008141107A2
(en)
|
2007-05-09 |
2008-11-20 |
Nitto Denko Corporation |
Compositions that include a hydrophobic compound and a polyamino acid conjugate
|
JP5532486B2
(ja)
|
2007-08-14 |
2014-06-25 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
Egf受容体を標的とするモノクローナル抗体175ならびにその誘導体および用途
|
US20100256098A1
(en)
*
|
2007-08-31 |
2010-10-07 |
The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services |
Compounds for inhibiting wip1, prodrugs and compositions thereof, and related methods
|
EP2262537A1
(en)
*
|
2008-03-06 |
2010-12-22 |
Nitto Denko Corporation |
Polymer paclitaxel conjugates and methods for treating cancer
|
WO2010075303A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Splicing factors with a puf protein rna-binding domain and a splicing effector domain and uses of same
|
WO2010075417A1
(en)
|
2008-12-23 |
2010-07-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Survivin specific t cell receptor for treating cancer
|
WO2010088160A1
(en)
|
2009-01-28 |
2010-08-05 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
T cell receptors and related materials and methods of use
|
US9616245B2
(en)
*
|
2009-03-16 |
2017-04-11 |
Rajah Vijay Kumar |
Method of treating cells with drug and radiation according to proton density
|
CN102448482A
(zh)
|
2009-03-27 |
2012-05-09 |
范安德尔研究所 |
甲状旁腺素肽和甲状旁腺素相关蛋白肽及使用方法
|
US9849146B2
(en)
|
2009-07-20 |
2017-12-26 |
Rutgers, The State University Of New Jersey |
Inhibition of nonsense mediated mRNA decay by drugs that prevent hypusination of eukaryotic initiation factor 5A
|
US8603814B2
(en)
|
2009-07-20 |
2013-12-10 |
Rutgers The State University Of New Jersey |
Method of inhibiting nonsense-mediated mRNA decay
|
WO2011032099A1
(en)
|
2009-09-11 |
2011-03-17 |
The Board Of Trustees Of The University Of Illinois |
Methods of treating diastolic dysfunction and related conditions
|
US20110076232A1
(en)
*
|
2009-09-29 |
2011-03-31 |
Ludwig Institute For Cancer Research |
Specific binding proteins and uses thereof
|
JP5934099B2
(ja)
|
2009-10-01 |
2016-06-15 |
アメリカ合衆国 |
抗血管内皮増殖因子受容体−2キメラ抗原受容体及び癌の治療のためのその使用
|
EP2488637B1
(en)
|
2009-10-16 |
2015-12-23 |
The University Of British Columbia |
Inhibitors of phosphatase and tensin homolog (pten) compositions, uses and methods
|
US20120208762A1
(en)
|
2009-10-27 |
2012-08-16 |
The Board Of Trustees Of The University Of Illinois |
Methods of Diagnosing Diastolic Dysfunction
|
WO2011060218A1
(en)
|
2009-11-13 |
2011-05-19 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Modulated programmed death ligand-1
|
EP2512503A4
(en)
|
2009-12-18 |
2013-08-21 |
Univ Indiana Res & Tech Corp |
COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR
|
MX2012008603A
(es)
|
2010-01-27 |
2013-01-25 |
Univ Indiana Res & Tech Corp |
Conjugados de antagonista de glucagon-agonista de gip y composiciones para el tratamiento de desordenes metabolicos y obesidad.
|
ES2575160T3
(es)
|
2010-03-15 |
2016-06-24 |
The Board Of Trustees Of The University Of Illinois |
Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G
|
CN103124740B
(zh)
|
2010-09-21 |
2015-09-02 |
美国卫生和人力服务部 |
抗-ssx-2t细胞受体和相关材料及使用方法
|
WO2012054825A1
(en)
|
2010-10-22 |
2012-04-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mage-a3 t cell receptors and related materials and methods of use
|
WO2012087943A2
(en)
|
2010-12-20 |
2012-06-28 |
The Regents Of The University Of Michigan |
Inhibitors of the epidermal growth factor receptor-heat shock protein 90 binding interaction
|
BR112013015389A2
(pt)
|
2010-12-22 |
2016-11-22 |
Univ Indiana Res & Tech Corp |
análogo de glucagon exibindo atividade de receptor gip
|
CN102675422B
(zh)
|
2011-03-15 |
2014-02-05 |
天津托普泰克生物科技有限公司 |
抗乙型肝炎病毒x蛋白多肽药物
|
IL285335B2
(en)
|
2011-04-08 |
2023-12-01 |
Us Health |
Chimeric antigen receptors against epidermal growth factor receptor variant III and their use in cancer treatment
|
CN102746378B
(zh)
|
2011-04-22 |
2014-10-22 |
天津托普泰克生物科技有限公司 |
抗脂肪酸合成酶多肽及其应用
|
EP2718308B1
(en)
|
2011-06-09 |
2017-05-17 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Pseudomonas exotoxin a with less immunogenic t cell and/or b cell epitopes
|
CN103857408B
(zh)
|
2011-06-22 |
2017-04-12 |
印第安那大学科技研究公司 |
胰高血糖素/glp‑1受体协同激动剂
|
IL290105B2
(en)
|
2011-09-15 |
2024-04-01 |
Us Health |
MAGE-recognizing T cell receptors are restricted to 1HLA–A or HLA–CW7
|
ES2656505T3
(es)
|
2011-09-16 |
2018-02-27 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Exotoxina A de Pseudomonas con epítopos de linfocitos B menos inmunogénicos
|
IN2014CN02906A
(sk)
|
2011-10-20 |
2015-07-03 |
Us Health |
|
RU2014117678A
(ru)
|
2011-11-17 |
2015-12-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью
|
CA3209571A1
(en)
|
2012-03-23 |
2013-09-26 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-mesothelin chimeric antigen receptors
|
EP2836239A1
(en)
|
2012-04-11 |
2015-02-18 |
The United States of America, as Represented By the Secretary, Department of Health and Human Services |
Chimeric antigen receptors targeting b-cell maturation antigen
|
EP3828197A1
(en)
|
2012-05-22 |
2021-06-02 |
The United States of America, as represented by the Secretary, Department of Health and Human Services |
Pharmaceutical composition comprising host cells encoding anti-ny-eso-1 t cell receptors
|
AU2013274078A1
(en)
|
2012-06-14 |
2015-01-29 |
Ambrx, Inc. |
Anti-PSMA antibodies conjugated to nuclear receptor ligand polypeptides
|
JP6300239B2
(ja)
|
2012-06-21 |
2018-03-28 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
Gip受容体活性を示すグルカゴンアナローグ
|
EP2864351B1
(en)
|
2012-06-21 |
2016-08-10 |
Indiana University Research and Technology Corporation |
Glucagon analogs exhibiting gip receptor activity
|
JP6461796B2
(ja)
|
2012-09-14 |
2019-01-30 |
アメリカ合衆国 |
Mhcクラスii拘束性mage−a3を認識するt細胞受容体
|
WO2014065961A1
(en)
|
2012-10-24 |
2014-05-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
M971 chimeric antigen receptors
|
US9790282B2
(en)
|
2013-03-25 |
2017-10-17 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-CD276 polypeptides, proteins, and chimeric antigen receptors
|
US9890369B2
(en)
|
2013-06-20 |
2018-02-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Cytolethal distending toxin subunit B conjugated or fused to Bacillus anthracis toxin lethal factor
|
US9822162B2
(en)
|
2013-07-15 |
2017-11-21 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Anti-human papillomavirus 16 E6 T cell receptors
|
EP3038641B1
(en)
|
2013-10-06 |
2019-04-17 |
The United States of America, as represented by The Secretary, Department of Health and Human Services |
Modified pseudomonas exotoxin a
|
RU2701346C1
(ru)
|
2013-12-06 |
2019-09-25 |
Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез |
Химерные антигенные рецепторы, специфичные в отношении рецептора тимусного стромального лимфопоэтина, и способы их применения
|
MA51794A
(fr)
|
2014-04-23 |
2020-05-06 |
Juno Therapeutics Inc |
Procédés d'isolation, de culture et de modification génétique de populations de cellules immunitaires pour thérapie adoptive
|
MX2016015383A
(es)
|
2014-05-29 |
2017-02-28 |
Us Health |
Receptores de celulas t anti - papilomavirus 16 e7 humano.
|
CN106536564B
(zh)
|
2014-06-02 |
2021-08-31 |
美国卫生和人力服务部 |
靶向cd-19的嵌合抗原受体
|
CN107075483A
(zh)
|
2014-07-15 |
2017-08-18 |
朱诺治疗学股份有限公司 |
用于过继细胞治疗的工程改造的细胞
|
TWI751102B
(zh)
|
2014-08-28 |
2022-01-01 |
美商奇諾治療有限公司 |
對cd19具專一性之抗體及嵌合抗原受體
|
SG10202104804PA
(en)
|
2014-10-20 |
2021-06-29 |
Juno Therapeutics Inc |
Methods and compositions for dosing in adoptive cell therapy
|
WO2016071343A1
(en)
|
2014-11-03 |
2016-05-12 |
Immures S.R.L. |
T cell receptors
|
TWI735418B
(zh)
|
2014-11-05 |
2021-08-11 |
美商奇諾治療有限公司 |
用於轉導作用及細胞處理之方法
|
ES2819553T3
(es)
|
2014-12-03 |
2021-04-16 |
Juno Therapeutics Inc |
Métodos y composiciones para terapia celular adoptiva
|
TWI718118B
(zh)
|
2015-01-16 |
2021-02-11 |
美商奇諾治療有限公司 |
針對ror1之特異性抗體及嵌合抗原受體
|
WO2016166568A1
(en)
|
2015-04-16 |
2016-10-20 |
Juno Therapeutics Gmbh |
Methods, kits and apparatus for expanding a population of cells
|
EP3303586A1
(en)
|
2015-05-29 |
2018-04-11 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
MA45489A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés de culture de cellules, kits et appareil associés
|
MA45488A
(fr)
|
2015-10-22 |
2018-08-29 |
Juno Therapeutics Gmbh |
Procédés, kits et appareil de culture de cellules
|
JP7195141B2
(ja)
|
2015-10-22 |
2022-12-23 |
ジュノ セラピューティクス ゲーエムベーハー |
形質導入のための方法、キット、作用物質および装置
|
MA44314A
(fr)
|
2015-11-05 |
2018-09-12 |
Juno Therapeutics Inc |
Récepteurs chimériques contenant des domaines induisant traf, et compositions et méthodes associées
|
WO2017079703A1
(en)
|
2015-11-05 |
2017-05-11 |
Juno Therapeutics, Inc. |
Vectors and genetically engineered immune cells expressing metabolic pathway modulators and uses in adoptive cell therapy
|
AU2016363025B2
(en)
|
2015-12-03 |
2021-04-08 |
Juno Therapeutics, Inc. |
Modified chimeric receptors and related compositions and methods
|
US11815514B2
(en)
|
2015-12-04 |
2023-11-14 |
Juno Therapeutics, Inc. |
Methods and compositions related to toxicity associated with cell therapy
|
EP3430549A1
(en)
|
2016-03-16 |
2019-01-23 |
Juno Therapeutics, Inc. |
Methods for adaptive design of a treatment regimen and related treatments
|
MA43758A
(fr)
|
2016-03-16 |
2018-11-28 |
Yuan Ji |
Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
|
EP4015536A1
(en)
|
2016-03-22 |
2022-06-22 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
Early intervention methods to prevent or ameliorate toxicity
|
AU2017261380A1
(en)
|
2016-05-06 |
2018-11-22 |
Editas Medicine, Inc. |
Genetically engineered cells and methods of making the same
|
CA3026453A1
(en)
|
2016-06-03 |
2017-12-07 |
Memorial Sloan-Kettering Cancer Center |
Adoptive cell therapies as early treatment options
|
MA45341A
(fr)
|
2016-06-06 |
2019-04-10 |
Hutchinson Fred Cancer Res |
Procédés de traitement de malignités de lymphocytes b au moyen d'une thérapie cellulaire adoptive
|
MA45491A
(fr)
|
2016-06-27 |
2019-05-01 |
Juno Therapeutics Inc |
Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés
|
CA3028002A1
(en)
|
2016-06-27 |
2018-01-04 |
Juno Therapeutics, Inc. |
Method of identifying peptide epitopes, molecules that bind such epitopes and related uses
|
WO2018005759A1
(en)
|
2016-07-01 |
2018-01-04 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Inhibitor of heme degradation for use to improve antibiotic treatment of mycobacterium tuberculosis infection
|
WO2018023093A1
(en)
|
2016-07-29 |
2018-02-01 |
Juno Therapeutics, Inc. |
Immunomodulatory polypeptides and related compositions and methods
|
CN110139873A
(zh)
|
2016-10-03 |
2019-08-16 |
朱诺治疗学股份有限公司 |
Hpv特异性结合分子
|
WO2018102612A1
(en)
|
2016-12-02 |
2018-06-07 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
EP3548083A1
(en)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics, Inc. |
Methods for modulation of car-t cells
|
MA46963A
(fr)
|
2016-12-03 |
2019-10-09 |
Juno Therapeutics Inc |
Méthodes pour déterminer le dosage de céllules car-t
|
CA3045338A1
(en)
|
2016-12-05 |
2018-06-14 |
Juno Therapeutics, Inc. |
Production of engineered cells for adoptive cell therapy
|
WO2018132518A1
(en)
|
2017-01-10 |
2018-07-19 |
Juno Therapeutics, Inc. |
Epigenetic analysis of cell therapy and related methods
|
CN110418802A
(zh)
|
2017-01-20 |
2019-11-05 |
朱诺治疗学有限公司 |
细胞表面缀合物及相关的细胞组合物和方法
|
JP7178355B2
(ja)
|
2017-02-28 |
2022-11-25 |
エンドサイト・インコーポレイテッド |
Car t細胞療法のための組成物および方法
|
MX2019012017A
(es)
|
2017-04-07 |
2020-02-12 |
Juno Therapeutics Inc |
Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados.
|
NZ758485A
(en)
|
2017-04-27 |
2024-02-23 |
Juno Therapeutics Gmbh |
Oligomeric particle reagents and methods of use thereof
|
JP7379164B2
(ja)
|
2017-06-02 |
2023-11-14 |
ジュノー セラピューティクス インコーポレイテッド |
細胞療法に関連する毒性に関する製造物品および方法
|
CN111225675B
(zh)
|
2017-06-02 |
2024-05-03 |
朱诺治疗学股份有限公司 |
使用过继细胞疗法治疗的制品和方法
|
CN109517820B
(zh)
|
2017-09-20 |
2021-09-24 |
北京宇繁生物科技有限公司 |
一种靶向HPK1的gRNA以及HPK1基因编辑方法
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
HPV-SPECIFIC BINDING MOLECULES
|
US20210254000A1
(en)
|
2017-11-01 |
2021-08-19 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
BR112020008323A2
(pt)
|
2017-11-01 |
2020-11-03 |
Juno Therapeutics Inc |
anticorpos e receptores de antígenos quiméricos específicos para antígeno de maturação de células b
|
AU2018360800A1
(en)
|
2017-11-01 |
2020-05-14 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for B-cell maturation antigen (BCMA)
|
BR112020008340A2
(pt)
|
2017-11-01 |
2020-11-17 |
Juno Therapeutics Inc |
processo para gerar composições terapêuticas de células modificadas
|
CA3081456A1
(en)
|
2017-11-01 |
2019-05-09 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of tgfbr2 in t cells for immunotherapy
|
US20230137729A1
(en)
|
2017-11-06 |
2023-05-04 |
Editas Medicine, Inc. |
Methods, compositions and components for crispr-cas9 editing of cblb in t cells for immunotherapy
|
EP3716980A1
(en)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics, Inc. |
Methods for dosing and for modulation of genetically engineered cells
|
US20210207080A1
(en)
|
2017-12-08 |
2021-07-08 |
Juno Therapeutics, Inc. |
Serum-free media formulation for culturing cells and methods of use thereof
|
SG11202005272SA
(en)
|
2017-12-08 |
2020-07-29 |
Juno Therapeutics Inc |
Process for producing a composition of engineered t cells
|
WO2019113559A2
(en)
|
2017-12-08 |
2019-06-13 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
JP2021512147A
(ja)
|
2018-01-22 |
2021-05-13 |
エンドサイト・インコーポレイテッドEndocyte, Inc. |
Car t細胞の使用方法
|
EP3746117A1
(en)
|
2018-01-31 |
2020-12-09 |
Celgene Corporation |
Combination therapy using adoptive cell therapy and checkpoint inhibitor
|
US20210046159A1
(en)
|
2018-03-09 |
2021-02-18 |
Ospedale San Raffaele S.R.L. |
Il-1 antagonist and toxicity induced by cell therapy
|
US11471489B2
(en)
|
2018-04-05 |
2022-10-18 |
Juno Therapeutics, Inc. |
T cell receptors and engineered cells expressing same
|
SG11202009446TA
(en)
|
2018-04-05 |
2020-10-29 |
Juno Therapeutics Inc |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
MA52656A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
|
KR20210057730A
(ko)
|
2018-08-09 |
2021-05-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
조작 세포 및 이의 조성물 생성 방법
|
EA202190469A1
(ru)
|
2018-08-09 |
2021-06-28 |
Джуно Терапьютикс, Инк. |
Способы оценки интегрированных нуклеиновых кислот
|
WO2020043899A1
(en)
|
2018-08-31 |
2020-03-05 |
Invectys |
Chimeric antigen receptors against multiple hla-g isoforms
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
CA3117419A1
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
AU2019374103A1
(en)
|
2018-11-01 |
2021-05-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
|
JP2022512913A
(ja)
|
2018-11-06 |
2022-02-07 |
ジュノー セラピューティクス インコーポレイテッド |
遺伝子操作されたt細胞を作製するための方法
|
BR112021009420A2
(pt)
|
2018-11-16 |
2021-11-23 |
Juno Therapeutics Inc |
Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b
|
MX2021006244A
(es)
|
2018-11-30 |
2021-09-10 |
Juno Therapeutics Inc |
Metodos de dosificacion y tratamiento de canceres de celulas b en terapia celular adoptiva.
|
KR20210117260A
(ko)
|
2018-11-30 |
2021-09-28 |
주노 쎄러퓨티크스 인코퍼레이티드 |
입양 세포 요법을 사용한 치료방법
|
US20220096651A1
(en)
|
2019-01-29 |
2022-03-31 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
|
EP3952886A1
(en)
|
2019-04-10 |
2022-02-16 |
Elevatebio Technologies, Inc |
Flt3-specific chimeric antigen receptors and methods of using the same
|
CA3136737A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
BR112021021200A2
(pt)
|
2019-05-01 |
2021-12-21 |
Juno Therapeutics Inc |
Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos
|
AU2020280105A1
(en)
|
2019-05-22 |
2022-01-20 |
Massachusetts Institute Of Technology |
Circular RNA compositions and methods
|
CN112390894A
(zh)
|
2019-08-12 |
2021-02-23 |
广东东阳光药业有限公司 |
嵌合抗原受体及其应用
|
AU2020377043A1
(en)
|
2019-10-30 |
2022-06-02 |
Juno Therapeutics Gmbh |
Cell selection and/or stimulation devices and methods of use
|
EP4070097A1
(en)
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Methods related to toxicity and response associated with cell therapy for treating b cell malignancies
|
KR20220146480A
(ko)
|
2020-01-28 |
2022-11-01 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포 형질도입 방법
|
CN115916223A
(zh)
|
2020-04-10 |
2023-04-04 |
朱诺治疗学股份有限公司 |
与用靶向b细胞成熟抗原的嵌合抗原受体工程化的细胞疗法相关的方法和用途
|
US20230178239A1
(en)
|
2020-05-13 |
2023-06-08 |
Juno Therapeutics, Inc. |
Methods of identifying features associated with clinical response and uses thereof
|
CN116322788A
(zh)
|
2020-05-19 |
2023-06-23 |
奥纳治疗公司 |
环状rna组合物和方法
|
WO2021260186A1
(en)
|
2020-06-26 |
2021-12-30 |
Juno Therapeutics Gmbh |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
AU2022241654A1
(en)
|
2021-03-22 |
2023-09-28 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
CN117916256A
(zh)
|
2021-05-06 |
2024-04-19 |
朱诺治疗学有限公司 |
用于刺激和转导t细胞的方法
|
CN115404240A
(zh)
|
2021-05-28 |
2022-11-29 |
上海环码生物医药有限公司 |
制备环形rna的构建体、方法及其用途
|
WO2023081735A1
(en)
|
2021-11-03 |
2023-05-11 |
Celgene Corporation |
Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
|
TW202334080A
(zh)
|
2021-11-08 |
2023-09-01 |
美商歐納醫療公司 |
用於遞送環狀聚核苷酸之脂質奈米粒子組合物
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
WO2023164440A1
(en)
|
2022-02-22 |
2023-08-31 |
Juno Therapeutics, Inc. |
Proteinase 3 (pr3) chimeric autoantibody receptor t cells and related methods and uses
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
WO2023230548A1
(en)
|
2022-05-25 |
2023-11-30 |
Celgene Corporation |
Method for predicting response to a t cell therapy
|
WO2023231959A2
(en)
|
2022-05-30 |
2023-12-07 |
Shanghai Circode Biomed Co., Ltd |
Synthetic circular rna compositions and methods of use thereof
|
WO2023250400A1
(en)
|
2022-06-22 |
2023-12-28 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
WO2024006960A1
(en)
|
2022-06-29 |
2024-01-04 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids
|
WO2024031091A2
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
WO2024102762A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and lipid nanoparticle compositions for delivering polynucleotides
|
WO2024102730A1
(en)
|
2022-11-08 |
2024-05-16 |
Orna Therapeutics, Inc. |
Lipids and nanoparticle compositions for delivering polynucleotides
|
WO2024129778A2
(en)
|
2022-12-13 |
2024-06-20 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for baff-r and cd19 and methods and uses thereof
|
WO2024129982A2
(en)
|
2022-12-15 |
2024-06-20 |
Orna Therapeutics, Inc. |
Circular rna compositions and methods
|